Market Cap 7.09M
Revenue (ttm) 0.00
Net Income (ttm) -23.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.11
Volume 331,300
Avg Vol 7,624,862
Day's Range N/A - N/A
Shares Out 33.74M
Stochastic %K 56%
Beta 1.09
Analysts Strong Sell
Price Target $2.50

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 417 4364
Address:
9605 Medical Center Drive, Suite 270, Rockville, United States
WallStreetLiving
WallStreetLiving Aug. 4 at 1:28 PM
$TOVX Theriva successfully cleared every major capital-structure proposal at its 2026 Annual Meeting, including the long-delayed warrant exercise approval and the increase in authorized shares to 450 million. By finally securing quorum and stockholder support after multiple prior failed attempts, the company has removed a recurring overhang that had constrained its financing flexibility. With the warrants now exercisable and a larger share authorization in place, management has clearer pathways to raise capital or structure partnerships as clinical data on VCN-01 continues to mature. This procedural victory keeps the company positioned to advance its lead oncolytic virus program and pursue the strategic opportunities that remain the core of the long-term thesis.
0 · Reply
Thess5
Thess5 Aug. 4 at 1:27 PM
$TOVX Get ready for the pump and offering.
0 · Reply
focafoca99
focafoca99 Aug. 4 at 11:31 AM
$TOVX adopted an amendment to its 2020 Stock Incentive Plan, increasing authorized shares from 4.5 M to 6.5 M. https://www.rapidticker.com/news/tovx-sec-filing-d32312
1 · Reply
Tradelyfe
Tradelyfe Aug. 3 at 8:46 PM
$TOVX any news out of Spain? These fucks
0 · Reply
Lovelife68
Lovelife68 Aug. 3 at 7:02 PM
$TOVX Have the meeting in Maryland not Spain. We would be able to make it.
0 · Reply
Lovelife68
Lovelife68 Aug. 3 at 6:41 PM
$TOVX meeting at 3
0 · Reply
Tradelyfe
Tradelyfe Aug. 3 at 6:19 PM
$TOVX any positive news going to come at today’s meeting?
0 · Reply
WallStreetLiving
WallStreetLiving Aug. 3 at 2:22 PM
$TOVX voting now has gotten this stock to all time lows. TOVX must approve the warrant exercise proposal today because the New Warrants issued in the October 2025 inducement deal cannot be exercised until stockholders green-light the issuance of up to ~16.2 million shares under NYSE American rules. Those warrants carry an exercise price of $0.54 — more than double the current ~$0.21 stock price — so full exercise would still inject roughly $8.7 million in cash at a significant premium to the market. The accompanying authorized-share increase to 450 million is the necessary companion piece that gives the board the legal capacity to issue those shares if and when the warrants are exercised.
3 · Reply
dogood
dogood Aug. 3 at 11:56 AM
$TOVX without split I want to see her big move to $3 , many years this bio did not produce what we want
0 · Reply
Lost1found10
Lost1found10 Aug. 2 at 10:10 PM
$TOVX anyone voting yes on any account? If so, which one(s) & why?
2 · Reply
Latest News on TOVX
Theriva Biologics Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Theriva Biologics Proxy statement: Proxy filing


Theriva Biologics Proxy statement: Proxy filing

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

Theriva Biologics Proxy statement: Proxy filing


Theriva Biologics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 2 months ago

Theriva Biologics Slides: Corporate presentation


Theriva Biologics Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 3 months ago

Theriva Biologics Earnings release: Q1 2026


Theriva Biologics Quarterly report: Q1 2026

May 5, 2026, 4:00 PM EDT - 3 months ago

Theriva Biologics Quarterly report: Q1 2026


Theriva Biologics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Theriva Biologics Proxy statement: Proxy filing


Theriva Biologics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Theriva Biologics Proxy statement: Proxy filing


Theriva Biologics upgraded to Buy from Hold at Maxim

2026-03-31T11:54:39.000Z - 4 months ago

Theriva Biologics upgraded to Buy from Hold at Maxim


Theriva Biologics Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics sees cash runway into 1Q27

2026-03-12T12:05:50.000Z - 5 months ago

Theriva Biologics sees cash runway into 1Q27


Theriva Biologics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Theriva Biologics Earnings release: Q4 2025


Theriva Biologics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Theriva Biologics Annual report: Q4 2025


Theriva Biologics Proxy statement: Proxy Filing

Mar 4, 2026, 7:00 AM EST - 5 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

2026-02-18T13:16:44.000Z - 5 months ago

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics


Theriva Biologics Proxy statement: Proxy Filing

Jan 5, 2026, 7:00 AM EST - 7 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 8 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

2025-11-12T13:16:18.000Z - 9 months ago

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year


Theriva Biologics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Theriva Biologics Quarterly report: Q3 2025


Theriva Biologics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Theriva Biologics Earnings release: Q3 2025


Theriva Biologics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 9 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Proxy statement: Proxy Filing

Nov 10, 2025, 7:00 AM EST - 9 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 9 months ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 9 months ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Provides Response to Unusual Market Action

Oct 24, 2025, 2:31 PM EDT - 10 months ago

Theriva Biologics Provides Response to Unusual Market Action


Theriva Biologics sees cash runway into 1Q26

2025-08-11T12:12:22.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26


Theriva Biologics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q2 2025


Theriva Biologics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q2 2025


Theriva Biologics Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics sees cash runway into 1Q26

2025-05-14T12:52:08.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26


Theriva Biologics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q1 2025


Theriva Biologics Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q1 2025


Theriva Biologics Registration statement: Registration Filing

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Earnings release: Q4 2024


Theriva Biologics Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Annual report: Q4 2024


Theriva Biologics Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Registration statement: Registration Filing

Dec 10, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Quarterly report: Q3 2024


Theriva Biologics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Earnings release: Q3 2024


Theriva Biologics Proxy statement: Proxy Filing

Sep 30, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Registration statement: Registration Filing

Sep 23, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Proxy statement: Proxy Filing

Sep 18, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Registration statement: Registration Filing

Sep 11, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Registration statement: Registration Filing

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Announces Reverse Stock Split

Aug 16, 2024, 4:05 PM EDT - 2 years ago

Theriva Biologics Announces Reverse Stock Split


Theriva Biologics Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Quarterly report: Q2 2024


Theriva Biologics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q2 2024


Theriva Biologics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Quarterly report: Q1 2024


Theriva Biologics Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q1 2024


Theriva Biologics Registration statement: Registration Filing

May 2, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing


Theriva Biologics Earnings Call Transcript: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings Call Transcript: Q4 2023


Theriva Biologics Annual report: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Annual report: Q4 2023


Theriva Biologics Earnings release: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q4 2023


Theriva Biologics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Earnings Call Transcript: Q3 2023


Theriva Biologics Quarterly report: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Quarterly report: Q3 2023


Theriva Biologics Proxy statement: Proxy Filing

Aug 16, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Proxy statement: Proxy Filing

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing


Theriva Biologics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q2 2023


Theriva Biologics Quarterly report: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q2 2023


Theriva Biologics Earnings Call Transcript: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q1 2023


Theriva Biologics Quarterly report: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q1 2023


WallStreetLiving
WallStreetLiving Aug. 4 at 1:28 PM
$TOVX Theriva successfully cleared every major capital-structure proposal at its 2026 Annual Meeting, including the long-delayed warrant exercise approval and the increase in authorized shares to 450 million. By finally securing quorum and stockholder support after multiple prior failed attempts, the company has removed a recurring overhang that had constrained its financing flexibility. With the warrants now exercisable and a larger share authorization in place, management has clearer pathways to raise capital or structure partnerships as clinical data on VCN-01 continues to mature. This procedural victory keeps the company positioned to advance its lead oncolytic virus program and pursue the strategic opportunities that remain the core of the long-term thesis.
0 · Reply
Thess5
Thess5 Aug. 4 at 1:27 PM
$TOVX Get ready for the pump and offering.
0 · Reply
focafoca99
focafoca99 Aug. 4 at 11:31 AM
$TOVX adopted an amendment to its 2020 Stock Incentive Plan, increasing authorized shares from 4.5 M to 6.5 M. https://www.rapidticker.com/news/tovx-sec-filing-d32312
1 · Reply
Tradelyfe
Tradelyfe Aug. 3 at 8:46 PM
$TOVX any news out of Spain? These fucks
0 · Reply
Lovelife68
Lovelife68 Aug. 3 at 7:02 PM
$TOVX Have the meeting in Maryland not Spain. We would be able to make it.
0 · Reply
Lovelife68
Lovelife68 Aug. 3 at 6:41 PM
$TOVX meeting at 3
0 · Reply
Tradelyfe
Tradelyfe Aug. 3 at 6:19 PM
$TOVX any positive news going to come at today’s meeting?
0 · Reply
WallStreetLiving
WallStreetLiving Aug. 3 at 2:22 PM
$TOVX voting now has gotten this stock to all time lows. TOVX must approve the warrant exercise proposal today because the New Warrants issued in the October 2025 inducement deal cannot be exercised until stockholders green-light the issuance of up to ~16.2 million shares under NYSE American rules. Those warrants carry an exercise price of $0.54 — more than double the current ~$0.21 stock price — so full exercise would still inject roughly $8.7 million in cash at a significant premium to the market. The accompanying authorized-share increase to 450 million is the necessary companion piece that gives the board the legal capacity to issue those shares if and when the warrants are exercised.
3 · Reply
dogood
dogood Aug. 3 at 11:56 AM
$TOVX without split I want to see her big move to $3 , many years this bio did not produce what we want
0 · Reply
Lost1found10
Lost1found10 Aug. 2 at 10:10 PM
$TOVX anyone voting yes on any account? If so, which one(s) & why?
2 · Reply
Zeestallion
Zeestallion Aug. 2 at 7:36 PM
VIVS - 🔥 folks I'm pounding the table here. 💰 Management expecting a 500%+ Revenue Growth 💎 Eli Lilly a TRILLION dollar pharmaceutical company backing this project ✅️ Liver and GI models show high in ADCs 🔥 Their lab models are better at predicting real human side effects than the old animal tests. That's why big pharma is starting to pay attention. ✅️ Eli Lilly knows this is a game changer for big pharma companies $INDO $TOVX $DRUG $IPW
0 · Reply
Bodiddley2
Bodiddley2 Jul. 30 at 7:27 PM
$TOVX Any guesses on what new name will be? Was Adeona biologics then Synthetic biologics then Theriva biologics. I’m personally guessing Thievery Biologics!!
0 · Reply
Lovelife68
Lovelife68 Jul. 30 at 2:03 PM
$TOVX August 3
0 · Reply
winners234
winners234 Jul. 28 at 11:41 PM
$TOVX 👀
0 · Reply
Lovelife68
Lovelife68 Jul. 28 at 1:01 PM
$TOVX Who’s going to Spain for Shareholders meeting? Will Shallcross show up or not?
0 · Reply
ZACHSPIZZA
ZACHSPIZZA Jul. 27 at 4:15 PM
$TOVX 💤
1 · Reply
StockBoySam
StockBoySam Jul. 27 at 5:24 AM
$TOVX I Agree! VOTE NO!
0 · Reply
Suge1027
Suge1027 Jul. 24 at 7:47 PM
$TOVX I was going to sell for a loss but I will stick around to see how this plays out. Also voting no.
0 · Reply
Flazz72
Flazz72 Jul. 24 at 3:51 PM
$TOVX Look at this VERY INTERESTING work offered by Newsweed. https://newsweedcom.substack.com/p/shareholder-investigative-report?r=1042mx&triedRedirect=true The hypothesis regarding possible stock manipulation is quite compelling. All shareholders should VOTE NO on all issues.
0 · Reply
Lovelife68
Lovelife68 Jul. 24 at 2:37 PM
$TOVX Vote no!
0 · Reply
pepeber
pepeber Jul. 23 at 5:46 AM
$TOVX A ridiculous valuation of €10M—even accounting for future dilution and the company's poor state; an oncology asset nearing Phase 3 is worth at least €100–150M (see comparables). Once they announce a collaboration to launch the Phase 3 trial for VCN-1, the value will multiply tenfold.
0 · Reply
neily51
neily51 Jul. 21 at 6:10 PM
$TOVX told you so corrupt company
0 · Reply